DUBLIN, December 03, 2021--(BUSINESS WIRE)--The "Global Biosimilars Partnering Terms and Agreements 2010 to 2021" report has been added to ResearchAndMarkets.com's offering.
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.
Global Biosimilars Partnering Terms and Agreements 2010 to 2021 includes:
Trends in Biosimilars dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 170 Biosimilars deal records and contract documents where available
The leading Biosimilar deals by value since 2010
Most active Biosimilars dealmakers since 2010
The leading Biosimilars partnering resources
In Global Biosimilars Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:
Stage of development at signing
Deal component type
Specific therapy and technology target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Biosimilars dealmaking
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates
Chapter 3 - Leading Biosimilars deals
3.2. Top Biosimilars deals by value
Chapter 4 - Most active Biosimilars dealmakers
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles
Chapter 5 - Biosimilars contracts dealmaking directory
5.2. Biosimilars contracts dealmaking directory
Chapter 6 - Biosimilars dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 - Biosimilars deals by company A-Z
Appendix 2 - Biosimilars deals by stage of development
Appendix 3 - Biosimilars deals by deal type
Appendix 4 - Biosimilars deals by therapy area
Appendix 5 - Deal type definitions
JAMP Pharma Group
Walter and Eliza Hall Institute
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Algorithme Pharma Holdings
Chemo Sa Lugano
For more information about this report visit https://www.researchandmarkets.com/r/krrkae
View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005275/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900